We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-2.68%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.3B
AUM Growth
-$1.1B
Cap. Flow
-$283M
Cap. Flow %
-1.64%
Top 10 Hldgs %
87.61%
Holding
112
New
6
Increased
21
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$42.9M
2
ROIV icon
Roivant Sciences
ROIV
+$41.6M
3
ABCL icon
AbCellera Biologics
ABCL
+$40.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.6M
5
IMGN
Immunogen Inc
IMGN
+$17.9M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$469M
2
KYNB
Kyntra Bio
KYNB
+$39.7M
3
BPMC
Blueprint Medicines
BPMC
+$15M
4
KRYS icon
Krystal Biotech
KRYS
+$13.6M
5
VSTM icon
Verastem
VSTM
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNLI icon
26
Denali Therapeutics
DNLI
$3.79B
$42.9M 0.25%
1,455,322
+366,584
+34% +$10.3M
KNSA icon
27
Kiniksa Pharmaceuticals
KNSA
$6.21B
$39.6M 0.23%
2,809,577
+10,000
+0.4% +$134K
CERS icon
28
Cerus
CERS
$575M
$39.5M 0.23%
16,067,558
– –
NRIX icon
29
Nurix Therapeutics
NRIX
$2.46B
$38.8M 0.22%
3,882,125
– –
RARE icon
30
Ultragenyx Pharmaceutical
RARE
$2.5B
$36.1M 0.21%
783,059
+312,085
+66% +$14.5M
JBIO
31
Jade Biosciences
JBIO
$1.18B
$33.7M 0.19%
56,099
– –
IGMS
32
DELISTED
IGM Biosciences
IGMS
$29.1M 0.17%
3,157,210
+554
+0% +$6.21K
XENE icon
33
Xenon Pharmaceuticals
XENE
$6.19B
$28.9M 0.17%
751,639
– –
IMGN
34
DELISTED
Immunogen Inc
IMGN
$28.7M 0.17%
+1,520,097
New +$17.9M
DBVT
35
DBV Technologies
DBVT
$795M
$27.8M 0.16%
1,461,426
– –
VERV
36
DELISTED
Verve Therapeutics
VERV
$26.6M 0.15%
1,416,530
– –
TSVT
37
DELISTED
2seventy bio
TSVT
$25.3M 0.15%
2,497,526
– –
IDYA icon
38
IDEAYA Biosciences
IDYA
$3.46B
$25M 0.14%
1,062,123
+229,354
+28% +$4.72M
STOK icon
39
Stoke Therapeutics
STOK
$1.83B
$22.6M 0.13%
2,130,238
+14,822
+0.7% +$158K
BCYC
40
Bicycle Therapeutics
BCYC
$270M
$21.5M 0.12%
843,814
– –
GLUE icon
41
Monte Rosa Therapeutics
GLUE
$1.85B
$20.7M 0.12%
3,023,951
+2,648,856
+706% +$17.1M
CABA icon
42
Cabaletta Bio
CABA
$432M
$20.6M 0.12%
1,594,000
+250,000
+19% +$2.71M
KRYS icon
43
Krystal Biotech
KRYS
$10.7B
$20M 0.12%
169,934
-132,782
-44% -$13.6M
SMMT icon
44
Summit Therapeutics
SMMT
$9.88B
$15.8M 0.09%
6,304,705
– –
ANAB icon
45
AnaptysBio
ANAB
$1.54B
$15.8M 0.09%
775,924
– –
PRME icon
46
Prime Medicine
PRME
$544M
$15.1M 0.09%
1,028,466
– –
PACB icon
47
Pacific Biosciences
PACB
$438M
$15M 0.09%
1,127,782
– –
RLAY icon
48
Relay Therapeutics
RLAY
$4.01B
$14.6M 0.08%
1,160,117
+876,117
+308% +$10.9M
SPRY icon
49
ARS Pharmaceuticals
SPRY
$574M
$13.4M 0.08%
2,006,451
– –
DAWN
50
DELISTED
Day One Biopharmaceuticals
DAWN
$11.9M 0.07%
+1,000,000
New +$13.1M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Baker Bros. Advisors held 112 positions worth $17.3B, down 6% from $18.4B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Baker Bros. Advisors's Q2 2023 filing shows 6 new, 21 increased, 12 reduced and 5 closed positions. Its largest new stake was Immunogen Inc: 1,520,097 shares worth $28.7M. The largest sale was Seagen Inc. Common Stock, an estimated $469M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2023 buy was Immunogen Inc: 1,520,097 shares worth $28.7M.
  • Baker Bros. Advisors added most to Kymera Therapeutics in Q2 2023, an estimated $42.9M increase.
  • Baker Bros. Advisors's biggest Q2 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $469M.
  • Baker Bros. Advisors fully exited Blueprint Medicines in Q2 2023, selling an estimated $15M.
  • Baker Bros. Advisors's ten largest holdings make up 88% of its $17.3B portfolio in Q2 2023.
  • Baker Bros. Advisors opened 6 new positions and closed 5 in Q2 2023.
  • Baker Bros. Advisors's portfolio value fell 6% quarter-over-quarter to $17.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.